2024
Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial
Gottlieb A, Strober B, Kokolakis G, Merola J, Zheng M, Langley R, Tang M, Hofmann P, Thoma C, Warren R. Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s409. DOI: 10.25251/skin.8.supp.409.Peer-Reviewed Original ResearchGeneralized pustular psoriasisDermatology Life Quality IndexDermatology Life Quality Index scoresGeneralized pustular psoriasis flaresPustular psoriasisVisits up to weekWeek 4Results Baseline characteristicsLength of diseaseLife Quality IndexLife-threatening diseasePlacebo groupHigh-doseSkin pustulesBaseline characteristicsSpesolimabFlare preventionPlaceboDLQI scoreQuality of lifePatientsWeeksPsoriasisScoresDiseaseSpesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP): a plain language summary of the Effisayil™ 2 study
Morita A, Strober B, Burden A, Choon S, Anadkat M, Marrakchi S, Tsai T, Gordon K, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl M. Spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP): a plain language summary of the Effisayil™ 2 study. Future Rare Diseases 2024, 4: frd57. DOI: 10.2217/frd-2023-0023.Peer-Reviewed Original ResearchGeneralized pustular psoriasisGeneralized pustular psoriasis flaresPustular psoriasisHigh dosesQuality of lifePrevention of flaresCompared to placeboLife-threatening diseasePrevent flaresSpesolimabGPP flaresClinical studiesMedium doseSkin symptomsDoseUnwanted effectsPlaceboPsoriasisSymptomsDrugPustulesWeeksDisease
2023
POS1538 SAFETY OF GUSELKUMAB ACROSS DIVERSE PATIENT SUBGROUPS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2/3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS
Coates L, Strober B, Yu J, Leibowitz E, Rowland K, Kollmeier A, Miller M, Wang Y, LI S, Chakravarty S, Chan D, Shawi M, Yang Y, Lebwohl M, Rahman P. POS1538 SAFETY OF GUSELKUMAB ACROSS DIVERSE PATIENT SUBGROUPS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2/3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS. 2023, 1134-1135. DOI: 10.1136/annrheumdis-2023-eular.1917.Peer-Reviewed Original ResearchPsoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities
Blauvelt A, Gondo G, Bell S, Echeverría C, Schmitt-Egenolf M, Skov L, van de Kerkhof P, Howard L, Strober B. Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities. Journal Of Psoriasis And Psoriatic Arthritis 2023, 8: 100-106. PMID: 39296315, PMCID: PMC11361513, DOI: 10.1177/24755303231160683.Peer-Reviewed Original ResearchPsoriasis Area Severity IndexBody surface area involvementPatient-reported outcome measuresSurface area involvementDisease-specific qualityQuality of lifeExtensive psoriasisPsoriasis severityArea involvementPatient burdenOutcome measuresSevere diseaseClinical experienceSeverity IndexPsoriasisDiseasePresent studyPatientsSeverity
2021
S930 Safety of Ustekinumab Across Approved Adult Indications: Pooled Safety Analysis in Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis Through up to 5 Years
Long M, Danese S, Ott E, Gasink C, Miao Y, Baker T, Tikhonov I, Rahman P, Strober B, Loftus E. S930 Safety of Ustekinumab Across Approved Adult Indications: Pooled Safety Analysis in Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis Through up to 5 Years. The American Journal Of Gastroenterology 2021, 116: s441-s441. DOI: 10.14309/01.ajg.0000777252.35443.aa.Peer-Reviewed Original Research
2020
Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A. Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal Of The American Academy Of Dermatology 2020, 84: 432-470. PMID: 32738429, DOI: 10.1016/j.jaad.2020.07.087.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisAAD-NPF GuidelinesRole of dermatologistsImportant clinical questionsAlternative medicine modalitiesUnited States populationTopical therapyPsoriasis managementTopical agentsMultisystem diseaseTreatment recommendationsClinical questionsAlternative medicinePsoriasisAvailable evidenceSeverity measuresCareTreatmentGuidelinesSeverity assessment methodsPatientsTherapyStates populationDermatologistsDiseaseJoint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies
Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal Of The American Academy Of Dermatology 2020, 82: 1445-1486. PMID: 32119894, DOI: 10.1016/j.jaad.2020.02.044.Peer-Reviewed Original ResearchConceptsDermatology–National Psoriasis Foundation guidelinesManagement of psoriasisTreatment of psoriasisChronic inflammatory diseaseFumaric acid estersMultiple organ systemsJoint American AcademyNonbiologic medicationsNonbiologic therapiesInflammatory diseasesFoundation guidelinesNew therapiesAmerican AcademyOrgan systemsMedicationsPsoriasisTherapyTreatmentDiseaseGuidelinesTofacitinibAcitretinPatientsApremilastPrescribers
2019
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater E, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal Of The American Academy Of Dermatology 2019, 82: 161-201. PMID: 31703821, DOI: 10.1016/j.jaad.2019.08.049.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAnthralinBiological ProductsCalcineurin InhibitorsCardiovascular DiseasesChildChild, PreschoolCoal TarComorbidityCyclosporineDermatologic AgentsDyslipidemiasEvidence-Based MedicineHumansInfantInfant, NewbornInflammatory Bowel DiseasesInsulin ResistanceMental HealthMetabolic SyndromeMethotrexateNicotinic AcidsObesityPhotochemotherapyPsoriasisRetinoidsConceptsPediatric patientsDermatology–National Psoriasis Foundation guidelinesTreatment of psoriasisImportant clinical questionsEvidence-based recommendationsJoint American AcademyPsoriasis managementInflammatory diseasesFoundation guidelinesClinical questionsPatientsAmerican AcademyPsoriasisProvider interactionsGuideline sectionsUnique physiologyGuidelinesPharmacokineticsDiseaseCareMultisystemCorrection to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Ghosh S, Gensler L, Yang Z, Gasink C, Chakravarty S, Farahi K, Ramachandran P, Ott E, Strober B. Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Safety 2019, 42: 809-809. PMID: 31012051, PMCID: PMC6520476, DOI: 10.1007/s40264-019-00816-3.Peer-Reviewed Original ResearchJoint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal Of The American Academy Of Dermatology 2019, 80: 1073-1113. PMID: 30772097, DOI: 10.1016/j.jaad.2018.11.058.Peer-Reviewed Original ResearchMeSH KeywordsArthritis, PsoriaticCardiovascular DiseasesComorbidityDyslipidemiasEvidence-Based MedicineHumansHypertensionInflammatory Bowel DiseasesKidney DiseasesLife StyleLiver DiseasesLung Diseases, ObstructiveMental HealthMetabolic SyndromeNeoplasmsObesityPatient Education as TopicPhysician's RolePsoriasisQuality of LifeSleep Apnea SyndromesJoint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal Of The American Academy Of Dermatology 2019, 80: 1029-1072. PMID: 30772098, DOI: 10.1016/j.jaad.2018.11.057.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisAAD-NPF GuidelinesInflammatory multisystem diseaseImportant clinical questionsBiologic agentsPsoriasis managementMultisystem diseaseTreatment recommendationsClinical questionsUS populationPsoriasisAvailable evidenceCareTreatmentGuidelinesPatientsDermatologistsDiseaseBiologicsUstekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, Ramachandran P, Ott E, Strober BE. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Safety 2019, 42: 751-768. PMID: 30739254, PMCID: PMC6520311, DOI: 10.1007/s40264-019-00797-3.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsPsoriatic arthritisRegistrational trialsCrohn's diseaseMajor adverse cardiovascular eventsUstekinumab-treated patientsAdverse cardiovascular eventsSevere plaque psoriasisConsistent safety profileSevere Crohn's diseaseActive psoriatic arthritisClinical development programUstekinumab doseCardiovascular eventsPlaque psoriasisBiologic agentsPsoriatic patientsInduction doseSafety profileIncidence rateSafety dataPatientsDiseaseSafety eventsWeeks
2018
Clinical Goals and Barriers to Effective Psoriasis Care
Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, Cohen AD, de la Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, Iversen L, Kleyn CE, Leonardi CL, Lynde CW, Ryan C, Theng CT, Valenzuela F, Vender R, Wu JJ, Young HS, Kimball AB. Clinical Goals and Barriers to Effective Psoriasis Care. Dermatology And Therapy 2018, 9: 5-18. PMID: 30578464, PMCID: PMC6380974, DOI: 10.1007/s13555-018-0279-5.Peer-Reviewed Original ResearchPsoriasis patientsInternational Psoriasis CouncilResource-poor countriesPsoriasis careAutoimmune diseasesOptimal careEarly treatmentTreatment goalsInnovative therapiesTherapeutic efficacyClinical goalsPatientsTreatment barriersModerate formsDisease impactKey opinion leadersCareClinical sciencePsoriasisGreater gainsTherapyGreater understandingDisease
2015
The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Wald J, Klufas D, Strober B. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis. Journal Of Drugs In Dermatology 2015, 14: 888-92. PMID: 26267735.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdolescentAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalCyclosporineDermatologic AgentsDrug Therapy, CombinationEtanerceptFemaleFoot DermatosesHand DermatosesHumansImmunosuppressive AgentsInfliximabMaleMethotrexateMiddle AgedMycophenolic AcidPsoriasisSeverity of Illness IndexThalidomideUstekinumabYoung Adult
2014
Understanding therapeutic pathways and comorbidities in psoriasis.
Gordon K, Strober B. Understanding therapeutic pathways and comorbidities in psoriasis. Seminars In Cutaneous Medicine And Surgery 2014, 33: s20-3. PMID: 24979540, DOI: 10.12788/j.sder.0067.Peer-Reviewed Original ResearchConceptsImmunologic pathwaysQuality of lifeJoint symptomsBiologic medicationsPathophysiologic pathwaysSystemic diseaseTherapeutic armamentariumInflammatory diseasesTherapeutic pathwaysPsoriasisKeratinocyte proliferationMedicationsHealth risksDiseasePathwayComorbiditiesMorbiditySymptomsArmamentariumMortality
2013
Treatment of atopic dermatitis in pregnancy
Babalola O, Strober B. Treatment of atopic dermatitis in pregnancy. Dermatologic Therapy 2013, 26: 293-301. PMID: 23914886, DOI: 10.1111/dth.12074.Peer-Reviewed Original Research
2009
A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach
Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. Journal Of The American Academy Of Dermatology 2009, 61: s1-s46. PMID: 19527820, DOI: 10.1016/j.jaad.2009.03.017.Peer-Reviewed Original ResearchConceptsTreatment optionsSevere psoriasisAvailable evidence-based dataHistory of malignancyEfficacious treatment optionBreast-feeding womenMedical treatment optionsSystemic psoriasis therapiesEvidence-based dataDelphi consensus approachLatent tuberculosisPsoriatic diseaseLiver diseasePsoriasis therapyHealthy patientsTreatment recommendationsClinical trialsCardiovascular diseaseConsensus panelViral infectionPatientsOptimum managementDisease statesMedical evidenceDisease
2008
Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab
Marmon S, Strober B. Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab. Journal Of Investigative Dermatology 2008, 128: 2567-2569. PMID: 18927537, DOI: 10.1038/jid.2008.291.Peer-Reviewed Original ResearchNational Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening
Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG, Foundation P. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal Of The American Academy Of Dermatology 2008, 58: 1031-1042. PMID: 18313171, PMCID: PMC3716382, DOI: 10.1016/j.jaad.2008.01.006.Peer-Reviewed Original Research
2004
Toxic epidermal necrolysis‐like reaction secondary to colchicine overdose
Arroyo M, Sanders S, Yee H, Schwartz D, Kamino H, Strober B. Toxic epidermal necrolysis‐like reaction secondary to colchicine overdose. British Journal Of Dermatology 2004, 150: 581-588. PMID: 15030347, DOI: 10.1111/j.1365-2133.2004.05838.x.Peer-Reviewed Original Research